...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Blood Medicine >The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
【24h】

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies

机译：奥他木单抗在治疗对先前疗法有抵抗力的慢性淋巴细胞性白血病中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Chronic lymphocytic leukemia (CLL) is an indolent but incurable disease. Despite the improvement of the available therapies, the management of heavily-treated CLL patients represents a challenge for modern practitioners. Ofatumumab is a second-generation, fully human anti-CD20 monoclonal antibody that has shown activity in CLL patients who have failed very effective therapies such as fludarabine, alemtuzumab and rituximab. Potential benefits of ofatumumab include powerful complement-dependent cytotoxicity, less immunogenicity, faster infusions and activity in resistant CLL patients. Recently, the FDA has approved ofatumumab for the treatment of CLL patients who have failed fludarabine and alemtuzumab-based regimens. The aim of this review is to summarize the current knowledge regarding pharmacology, mechanism of action, pre-clinical and clinical development, and the role of ofatumumab for the treatment of CLL patients who have failed previous therapies. Further research is necessary to further define the role of ofatumumab in the treatment of CLL.
机译：摘要：慢性淋巴细胞性白血病（CLL）是一种顽固但无法治愈的疾病。尽管现有疗法有所改进，但对重症治疗的CLL患者的治疗仍是现代医生的挑战。 Ofatumumab是第二代完全人源抗CD20单克隆抗体，已在氟达拉滨，阿仑单抗和利妥昔单抗等非常有效的治疗失败的CLL患者中显示活性。 ofatumumab的潜在益处包括强大的补体依赖性细胞毒性，免疫原性降低，输注速度更快以及抗药性CLL患者的活性。最近，FDA已批准ofatumumab用于治疗以氟达拉滨和基于alemtuzumab的治疗方案失败的CLL患者。这篇综述的目的是总结有关药理学，作用机理，临床前和临床发展以及ofatumumab在治疗先前治疗失败的CLL患者中的作用的最新知识。为了进一步确定ofatumumab在CLL治疗中的作用，需要进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号